denkapparat Operations GmbH Makes New Investment in DexCom, Inc. $DXCM

denkapparat Operations GmbH acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the second quarter, HoldingsChannel reports. The firm acquired 7,070 shares of the medical device company’s stock, valued at approximately $476,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Reflection Asset Management purchased a new stake in DexCom in the 4th quarter valued at about $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth approximately $32,000. Wellington Grp LLC boosted its position in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares during the last quarter. Finally, DV Equities LLC purchased a new stake in DexCom in the fourth quarter valued at approximately $36,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the sale, the director directly owned 48,852 shares of the company’s stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the completion of the transaction, the executive vice president owned 126,043 shares in the company, valued at approximately $11,138,419.91. This trade represents a 1.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 65,777 shares of company stock worth $4,950,714. Corporate insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DXCM shares. Wells Fargo & Company lifted their target price on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 31st. William Blair upgraded DexCom to a “strong-buy” rating in a report on Friday, May 15th. UBS Group set a $96.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Citigroup reiterated a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Finally, Mizuho increased their price objective on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

DexCom Stock Down 2.0%

NASDAQ DXCM opened at $87.90 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59. The business has a 50 day moving average price of $81.24 and a two-hundred day moving average price of $72.35. The stock has a market cap of $33.17 billion, a PE ratio of 34.74, a P/E/G ratio of 1.50 and a beta of 1.42.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.48 earnings per share. As a group, sell-side analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.